3-morpholinopropyl 3-((3-(3,5-difluorophenyl)-6-oxopyridazin-1(6H)-yl)methyl)phenylcarbamate

ID: ALA3402765

Chembl Id: CHEMBL3402765

PubChem CID: 59849760

Max Phase: Preclinical

Molecular Formula: C25H26F2N4O4

Molecular Weight: 484.50

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C(Nc1cccc(Cn2nc(-c3cc(F)cc(F)c3)ccc2=O)c1)OCCCN1CCOCC1

Standard InChI:  InChI=1S/C25H26F2N4O4/c26-20-14-19(15-21(27)16-20)23-5-6-24(32)31(29-23)17-18-3-1-4-22(13-18)28-25(33)35-10-2-7-30-8-11-34-12-9-30/h1,3-6,13-16H,2,7-12,17H2,(H,28,33)

Standard InChI Key:  SAUCUXJYCROSSC-UHFFFAOYSA-N

Associated Targets(Human)

MET Tclin Hepatocyte growth factor receptor (10718 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PDE3A Tclin Phosphodiesterase 3 (1749 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PDE4A Tclin Phosphodiesterase 4 (3344 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 484.50Molecular Weight (Monoisotopic): 484.1922AlogP: 3.51#Rotatable Bonds: 8
Polar Surface Area: 85.69Molecular Species: NEUTRALHBA: 7HBD: 1
#RO5 Violations: HBA (Lipinski): 8HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 13.01CX Basic pKa: 7.16CX LogP: 3.31CX LogD: 3.11
Aromatic Rings: 3Heavy Atoms: 35QED Weighted: 0.49Np Likeness Score: -2.02

References

1. Dorsch D, Schadt O, Stieber F, Meyring M, Grädler U, Bladt F, Friese-Hamim M, Knühl C, Pehl U, Blaukat A..  (2015)  Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors.,  25  (7): [PMID:25736998] [10.1016/j.bmcl.2015.02.002]

Source